Post-COVID-19 outcomes of non-dialysis dependent chronic kidney disease patients: a national, multicenter, controlled study.
CKD
COVID-19
Outcomes
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
21
01
2022
accepted:
28
07
2022
pubmed:
12
8
2022
medline:
25
1
2023
entrez:
11
8
2022
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) has a higher mortality in the presence of chronic kidney disease (CKD). However, there has not been much research in the literature concerning the outcomes of CKD patients in the post-COVID-19 period. We aimed to investigate the outcomes of CKD patients not receiving renal replacement therapy. In this multicenter observational study, we included CKD patients with a GFR < 60 ml/min/1.73 m There were 173 patients in the COVID-19 group and 207 patients in the control group. Most patients (72.8%) were treated as inpatient in the COVID-19 group (intensive care unit hospitalization: 16.7%, acute kidney injury: 54.8%, needing dialysis: 7.9%). While there was no significant difference between the baseline creatinine values of the COVID-19 group and the control group (1.86 and 1.9, p = 0.978, respectively), on the 1st month, creatinine values were significantly higher in the COVID-19 group (2.09 and 1.8, respectively, p = 0.028). Respiratory system symptoms were more common in COVID-19 patients compared to the control group in the 1st month and 3rd month follow-ups (p < 0.001). Mortality at 3 months after the diagnosis of COVID-19 was significantly higher in the COVID-19 group than in the control group (respectively; 5.2% and 1.4%, p:0.037). Similarly, the rate of patients requiring dialysis for COVID-19 was significantly higher than the control group (respectively; 8.1% and 3.4%, p: 0.045). In CKD patients, COVID-19 was associated with increased mortality, as well as more deterioration in kidney function and higher need for dialysis in the post-COVID-19 period. These patients also had higher rate of ongoing respiratory symptoms after COVID-19.
Identifiants
pubmed: 35951255
doi: 10.1007/s11255-022-03329-8
pii: 10.1007/s11255-022-03329-8
pmc: PMC9366804
doi:
Substances chimiques
Creatinine
AYI8EX34EU
Types de publication
Multicenter Study
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
399-408Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
J Korean Med Sci. 2020 Dec 28;35(50):e434
pubmed: 33372426
J Am Soc Nephrol. 2021 Jan;32(1):151-160
pubmed: 32883700
Kidney Blood Press Res. 2021;46(4):452-459
pubmed: 34098555
JAMA Netw Open. 2021 Mar 1;4(3):e211095
pubmed: 33688965
Int Urol Nephrol. 2021 Aug;53(8):1623-1629
pubmed: 33389508
QJM. 2020 Nov 1;113(11):799-805
pubmed: 32840579
Pulmonology. 2021 Jul-Aug;27(4):328-337
pubmed: 33262076
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760
PLoS One. 2021 Aug 10;16(8):e0256023
pubmed: 34375366
Am J Kidney Dis. 2021 Feb;77(2):204-215.e1
pubmed: 32961245
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
EClinicalMedicine. 2020 Aug;25:100463
pubmed: 32838236
BMC Nephrol. 2020 Oct 27;21(1):449
pubmed: 33109103
Nephrol Dial Transplant. 2020 Dec 4;35(12):2083-2095
pubmed: 33275763
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
World J Urol. 2021 Aug;39(8):3121-3123
pubmed: 32488360
J Am Soc Nephrol. 2020 Sep;31(9):2145-2157
pubmed: 32669322
J Med Virol. 2021 Mar;93(3):1387-1395
pubmed: 33150973
Rev Med Virol. 2021 May;31(3):e2176
pubmed: 33022818
Kidney Int Rep. 2021 Oct;6(10):2565-2574
pubmed: 34307971
J Clin Med. 2021 May 25;10(11):
pubmed: 34070339
Thorax. 2021 Apr;76(4):399-401
pubmed: 33273026
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
Curr Res Transl Med. 2020 Nov;68(4):149-150
pubmed: 32917573
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652
Kidney Int. 2005 Feb;67(2):698-705
pubmed: 15673319